Introduction
The UK Cystic Fibrosis Gene Therapy Consortium is focused on the optimization of airway gene transfer for cystic fibrosis (CF), a monogenic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR). Viral and non-viral vectors have been administered to the nasal or airway epithelium of CF patients. [1] [2] [3] [4] [5] While proof-of-principle for expression of functional CFTR has been established, further optimization of gene transfer efficacy would be advantageous. Firstly, the lung poses several extracellular barriers, such as mucociliary clearance, mucus, the glycocalyx, tight junctions, as well as intracellular barriers, for example the endosome and nuclear membrane. 6 Attempts to overcome these barriers have included the use of mucolytic agents, for example, nacystelyn, mucus inhibitors such as glycopyrrolate, 7 and tight junction openers such as ethyleneglycol tetraacetate (EGTA) and sodium caprate. [8] [9] [10] Secondly, transgene expression in the clinical trials was low and transient, resulting in partial and shortlived correction of CFTR function. As CF is a lifelong disease, repeat administration or one-time stable transduction of lung stem cells will be needed. Progress in overcoming the low transduction efficiency has recently been made. Recombinant Sendai virus transduces airway epithelium very efficiently; 11 however, repeat administration of viral gene transfer agents (GTAs) is difficult owing to immune responses targeted against viruses. Recently, some reports suggested that adeno-associated virus (AAV) may differ in this respect, 12, 13 but successful readministration of AAV has not been confirmed in all studies. 14 Efforts are also being made to develop more efficient non-viral GTAs, because of their favorable safety profile and ability to be readministered. 15 In general, however, transfection efficiency with non-viral GTAs is lower than for viruses. One approach to overcome this problem has been the use of peptides to target the vector to receptors found on the apical surface of airway epithelial cells. For instance, targeting CFTR conjugates to the serpinenzyme complex receptor (sec-R) has been shown partially to correct chloride transport in the nasal epithelium of CF mice. 16 Another approach has been the development of nanoparticles, formed by condensing pDNA to molecules with a small enough size to allow efficient nuclear entry. This has resulted in up to 200-fold increases in airway gene transfer in vivo, compared to naked plasmid DNA (pDNA). 17 In addition to these approaches, methods employing the addition of energy, to either the vector or the host, have also been used to improve gene transfer in several organs. These include hydrodynamic delivery, 18 electroporation, 19 and sonoporation. 20, 21 Magnetofection is based on superparamagnetic nanoparticles forming complexes with pDNA, which are then attracted to strong, permanent magnets placed on the target area. Magnetic forces have been previously used to enhance delivery of anticancer drugs to tumors, 22 as well as in the context of gene therapy. Studies with viral vectors, as well as using a variety of cationic lipids and synthetic polymers have shown an increase in transfection efficiency in vitro. 23, 24 Magnetofection has also been applied successfully in vivo to increase delivery of pDNA in the gastrointestinal epithelium of rats and mice 23 and antisense molecules in cremaster blood vessels, upon administration through a catheter into the femoral artery of mice. 25 In both cases, the magnet was applied directly onto the 'target' area for up to 15 min. More recently, magnetofection has been used to transfect primary airway cells in vitro, as well as airway epithelium from porcine trachea, ex vivo. 26 However, no study to date has assessed the potential of this technique for in vivo airway transfection. The proposed mechanism for magnetofection is an increase in the concentration of the vector on the cell surface, thereby increasing the contact time and hence gene transfer. 27 Recent evidence suggests that the magnetic complexes enter the cell via endocytosis, as for standard non-viral vectors, as their uptake is reduced by inhibiting endosome activation and disruption of the cytoskeleton. 28 In these studies, cationic lipid 67 (GL67)/pDNA complexes or naked pDNA were coupled to TransMAG PEI , thus rendering them responsive to a magnetic field. TransMAG PEI consists of an iron oxide core coated with polyethylenimine (PEI). It binds GTAs via charge interactions leading to salt-induced aggregation of vector components and has been used in several of the studies mentioned above. We hypothesized that delivery of these magnetic complexes into the mouse nose in vivo, in the presence of a magnetic field, would enhance gene transfer to the nasal epithelium.
Results

Magnetofection increases gene transfer in vitro
Initial in vitro transfections were carried out to validate whether TransMAG PEI magnetic particles complexed with liposomes could produce robust expression of luciferase, and whether magnetofection could increase the gene transfer efficiency of cationic lipids. We first determined the optimal dose range for transfection of C127 cells, using Lipofectamine/pDNA complexes, with DNA doses ranging from 0.02 to 1.0 mg/well. Maximum luciferase expression was achieved with 0.2 mg/well (5.5 Â 10 GL67 has been previously optimized in our lab for in vivo gene delivery to the airway epithelium, and has also been used in several clinical trials. 29, 30 Here, we assessed if GL67/pDNA complexes can form active particles when combined with TransMAG PEI . In our experience, GL67 is not as efficient as Lipofectamine 2000 for in vitro transfections and we therefore used a dose of 0.2 mg pDNA/well. Exposure to the magnetic field led to a significant (Po0.01, n ¼ 6) 30-fold increase in gene expression at the 3:1, although significant increases were also seen with the 2:1 and 4:1 ratios (Figure 2) . Thus, the addition of TransMAG PEI and exposure to a magnetic Figure 1 Magnetofection of Lipofectamine/pDNA complexes in vitro. C127 cells were transfected with a suboptimal Lipofectamine/pDNA dose (0.04 mg DNA/well) complexed to varying amounts of TransMAG PEI and exposed to the magnetic field for 15 min. **Po0.01, ***Po0.001, compared to each respective control group without application of a magnet (closed bars); n ¼ 6 wells/condition. Figure 2 Magnetofection of GL67/pDNA complexes, in vitro. C127 cells were transfected with GL67/pDNA liposome complexes (0.2 mg DNA/well), coupled to TransMAG PEI at different ratios and exposed to the magnet for 15 min. *Po0.05 and **Po0.01, compared to their respective control groups without exposure to the magnetic field; n ¼ 6 wells/condition. 
Magnetofection of GL67/pDNA liposomes does not increase gene transfer in vivo
We next assessed magnetofection in the mouse nose, in vivo. For these experiments, TransMAG PEI was complexed to GL67/pDNA at 4:1 w:w ratio (TransMAG PEI : pDNA), at a dose of 80 mg pDNA/100 ml total volume, previously used in extensive studies of gene transfer to the murine nose. 31 We first assessed if the magnetic rod was powerful enough to attract the magnetic complexes onto the nasal epithelium. Iron fillings, as well as TransMAG PEI (free and bound to GL67/pDNA complexes), placed onto the external surface of one nostril could be readily moved by the magnet, placed against the contralateral nostril. We next, therefore, perfused TransMAG PEI -GL67/pDNA complexes onto the mouse nasal epithelium in the presence and absence of the magnetic rod. As shown in Figure 3 , the addition of the magnetic particles to the GL67/pDNA formulation resulted in an approximately 50-fold significant (Po0.01, n ¼ 6À8) decrease in gene expression. Further, exposure to the magnetic field for a total of approximately 30 min, during and after the perfusion, did not increase transfection efficiency.
We also noted that at these conditions, the formulation precipitated during the 15-min perfusion, with the precipitate formed being partially retained in the catheter. To determine the properties of the precipitated complexes, we took samples of equal volumes from the supernatant, as well as from the precipitate itself, and assessed their gene transfer capabilities in C127 cells in vitro (Figure 4 ). Luciferase expression in the precipitate fraction was approximately 90-fold higher compared to the supernatant (Po0.001, n ¼ 8). This suggests that either most of the pDNA was contained in the precipitate, or that this fraction contained a DNA complex with higher transfection efficiency. Exposure to a magnetic field did not increase gene expression for the precipitate sample; however, the gene transfer efficiency of the supernatant was increased approximately eightfold, although it did not reach statistical significance. It is likely that the precipitate contains the majority of pDNA, whereas the supernatant largely contains the minor fraction of magnetically labelled GL67/pDNA complexes. The missing magnetic field enhancement for the precipitate fraction might also be explained by the fact that this effectively sediments on the cells by gravitational force. Gravitational forces have been previously shown to achieve similar effect as magnetofection. 28 Prevention of precipitation neither improves transfection efficiency of TransMAG PEI ÀGL67/pDNA complexes, nor allows for augmentation within a magnetic field High DNA doses are a known prerequisite for in vivo gene transfer. This, in turn, is commonly recognized to induce the aggregation problems noted above. To overcome these problems, we next undertook a series of studies evaluating the contribution of total solution volume, TransMAG PEI :pDNA ratio, and order of mixing. In all cases, GL67/pDNA complexes were formed before the addition of the magnetic particles. Table 1 summarizes the different conditions tested. In general, increasing the pDNA concentration or the TransMAG PEI : pDNA ratio (w:w), at a given volume, increased precipitation. The mixing order of the magnetic particles and GL67/pDNA complexes, as well as their respective volume ratios (for details, see Materials and methods) were also reversed, but similar results were obtained (data not shown).
From the non-precipitated formulations, we chose 80 mg DNA (1:1 and 2:1 TransMAG PEI :pDNA w:w) for further experiments, because this allowed us to deliver our standard in vivo pDNA dose. Firstly, we assessed if Figure 3 In vivo magnetofection of murine nasal epithelium with GL67/pDNA complexes. Animals were perfused with GL67/ pDNA at the standard dose of 80 mg/100 ml, and GL67/pDNA complexed to TransMAG PEI at a 4:1 w:w ratio (TransMAG PEI : pDNA). Where indicated, animals were exposed to the magnetic field for approximately 30 min. **Po0.01, compared to the GL67/pDNA group; n ¼ 6-8 mice/group. Following precipitation, aliquots of equal volumes were taken from the supernatant and the precipitate, and diluted to deliver 0.2 mg DNA/50 ml/well in a 96-well plate. Cells were then exposed to the magnetic field for 15 min (open bars). ***Po0.001; compared to the precipitate fraction, in the absence of the magnetic field; n ¼ 8 wells/condition.
Magnetofection in the mouse nose S Xenariou et al these non-precipitated formulations retained the ability to respond to a magnetic field in vitro. A significant (Po0.001; n ¼ 8) fourfold increase in luciferase expression was seen with the 2:1 w:w ratio of TransMAG PEI : pDNA but not with the 1:1 ratio, in the presence of the magnet (data not shown). This formulation was, therefore, perfused onto the murine nasal epithelium, in vivo, and exposed to the magnetic field for a total of 90 min (75 min during the perfusion and 15 min afterwards). As in the previous in vivo experiment, the addition of TransMAG PEI to GL67/pDNA significantly (Po0.001; n ¼ 6À9) reduced gene expression by approximately 90-fold when compared to GL67/pDNA alone ( Figure 5) . Further, no effect of the application of the magnet was seen. Thus, despite optimization of TransMAG PEI complexes, gene transfer to the airway epithelia is significantly lower with these complexes and is not increased by application of a magnetic field.
Magnetofection using naked pDNA also does not increase gene transfer in vivo Naked pDNA has been previously used for lung gene transfer, 32 as well as in gene transfer studies with TransMAG PEI . 28 We assessed the effect of a magnetic field on these complexes. Optimal conditions for complexing TransMAG PEI to naked pDNA were established as for GL67/pDNA (Table 2) . TransMAG PEI complexed to pDNA at 1:1 and 2:1 (w:w ratio), in a total volume of 100 ml, was assessed in the mouse nose in vivo, as higher w:w ratios precipitated. Addition of TransMAG PEI showed a nonsignificant reduction in gene expression, when compared to standard naked pDNA formulations. Exposure to the magnetic field did not increase transfection efficiency ( Figure 6 ). Magnetofection with naked pDNA was also assessed using smaller, circular magnets, arranged into a stack. This setup ensured that the area with the strongest magnetic field gradient and thus, the greatest magnetic force (edges of the magnets), was focused directly onto the nasal epithelium. However, exposure to the magnetic field did not increase transfection (data not shown).
Discussion
We have assessed for the first time, if TransMAG PEI magnetic particles, complexed to either GL67/pDNA or naked pDNA, can increase gene transfer to airway epithelia in vivo, when exposed to an external magnetic 
Abbreviations: GL67, cationic lipid 67; pDNA, plasmid DNA. TransMAG PEI was added to the GL67/pDNA complexes at different weight:weight ratios. pDNA was used at 40 and 80 mg, in total volumes of 100 and 500 ml. The solutions were scored for precipitation 20 min after the addition of the magnetic particles. P: precipitated, |: non-precipitated.
Figure 5
In vivo magnetofetion with the optimized formulation. The optimal formulation (TransMAG PEI ÀGL67/pDNA, 80 mg/ 500 ml, 2:1, w:w) was tested in the mouse nose in vivo. Mice were exposed to the magnetic field during the perfusion (75 min) and for 15 min afterwards. Addition of magnetic particles significantly reduced gene expression compared to the GL67/pDNA, 80 mg/ 500 ml group (***Po0.001, n ¼ 6À9 mice/group). NS: nonsignificant. 100 m/100 ml | | P P Abbreviation: pDNA, plasmid DNA. TransMAG PEI was added to naked pDNA at different weight:weight ratios. A total of 100 mg of pDNA was used, in a total volume of 100 ml. The solutions were scored for precipitation 20 min after the addition of the magnetic particles. P: precipitated, |: nonprecipitated.
Figure 6
In vivo magnetofection with naked pDNA. TransMAG PEI was complexed to naked pDNA at a 1:1 and 2:1 w:w ratio. Mice were perfused with 100 mg pDNA/100 ml and where indicated they were exposed to the magnetic field for a total of 30 min. No significant difference was seen in any of the groups. n ¼ 8 mice/ group.
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S Xenariou et al field. However, despite successful generation of magnetic complexes, optimization of particles for in vivo administration and generation of a sufficiently strong magnetic field, no increase in gene transfer to the nasal epithelium could be shown. Magnetofection has successfully increased nucleic acid transfer, both in vitro and in several tissues in vivo. TransMAG PEI , in particular, has been shown to increase gene transfer to gastrointestinal epithelia of both rats and mice, 23 whereas different types of magnetic particles have been used to deliver antisense oligonucleotides into cremaster blood vessels upon administration through the murine femoral artery. 25 Huth et al. 28 have shown that magnetic plasmid DNA complexes are pulled onto the cell surface in vitro, when exposed to a magnetic field, increasing vector concentration on the cell membrane and thus its cellular uptake. 28 We, therefore, evaluated TransMAG PEI -based magnetofection as a potential way to enhance non-viral gene transfer to the airway epithelium in vivo.
Initial in vitro experiments showed that our formulation of TransMAG PEI was able to bind pDNA/liposome complexes and increase their transfection efficiency, when exposed to a magnetic field. Magnetofection did not enhance gene expression at the higher dose of pDNA (0.2 mg/well), possibly due to saturation of intracellular components involved in pDNA processing. However, it allowed a similar level of gene expression to be reached at an approximately fivefold lower (0.04 mg/well) dose of DNA. Similar findings have previously been reported by Plank et al. 27 Although the augmentation of transfection efficiency of GL67/pDNA complexes was modest in the presence of the magnet, this likely reflects the comparative inefficiency of GL67 in vitro, originally optimized for in vivo lung gene transfer. 33 GL67 has long been the 'gold standard' cationic lipid for in vivo airway gene transfer, and we, therefore, continued to evaluate TransMAG PEI -GL67/ pDNA complexes in the mouse nose, in vivo.
The mouse nose is a well-established model for airway gene transfer. In contrast to the murine lower airways, the mouse nose closely recapitulates the cellular components of the human nose. 34 It also offers easy access to airway epithelial cells, although the relative proportion of respiratory and olfactory epithelium varies in a frontal/rostral axis. 35 Thus, respiratory epithelium dominates the front 3 mm of the conducting passage, whereas olfactory epithelium is found further back. By placing the perfusion catheter approximately 2.5 mm into the nasal cavity, we were able to maximize perfusion of particles to our target respiratory epithelium.
We first used our standard in vivo formulation of GL67/pDNA complexes (0.8 mg pDNA/ml) complexed to TransMAG PEI (4:1 w:w, TransMAG PEI :pDNA). However, during the 15-min perfusion, large precipitates formed. The higher concentration of pDNA, and hence TransMAG PEI , may affect the charge interactions between the pDNA and the magnetic particles, as well as the overall shape and size of the complexes. This type of aggregation in the presence of high DNA concentrations has been a recurring feature in the development of nonviral gene transfer agents. Indeed, one of the unique features of GL67 has been its ability to complex high DNA content without aggregation. The reduction in gene expression following the addition of magnetic particles may, therefore, be owing to less pDNA being delivered. Alternatively, the physicochemical properties of GL67/ pDNA may have been critically altered. Overall, these results highlight the difficulties of transferring in vitro findings to in vivo applications.
We next carried out a series of experiments to optimize TransMAG PEI -GL67/pDNA complexes and identified two stable formulations. However, when tested in vitro, only the 2:1 ratio (TransMAG PEI :pDNA, w:w) responded to the magnetic field, suggesting that for the lower 1:1 ratio the vector components (lipid, magnetic particles, pDNA) were not suitably associated. This formulation was subsequently tested in vivo, where, as before, addition of magnetic particles to the GL67/pDNA complexes resulted in a reduction in gene expression, which did not increase after exposure to the magnetic field. However, out of necessity, GL67/pDNA complexes were reconstituted in water, whereas the TransMAG PEI -GL67/pDNA complexes in 150 mM saline. Previous studies have suggested that hypotonic solutions can increase gene transfer efficacy. 36 Thus, we cannot exclude that the control animals (GL67/pDNA) showed values higher than if we had been able to use saline as the diluent for this group. To characterize the magnetic particles further, particle sizing was attempted but the polydispersity index indicated that all solutions were too heterogeneous in size to provide accurate data. However, the broad range of particle diameter did not change upon addition of magnetic particles (data not shown).
The discrepancy between the in vitro and the in vivo performance of the magnetic complexes is a common feature of many gene transfer agents. It is likely a reflection of the different 'barriers' for gene transfer posed by the two systems, such as cell division in the in vitro model, the presence of cilia and mucociliary clearance in the in vivo model, and many other factors.
Our study was designed to assess whether existing formulations could be transferred from the in vitro setting to in vivo application in the respiratory epithelium. However, the difficulties arose, as our mouse model, owing to the spatial restrictions, required fairly high vector concentrations, which were difficult to formulate with ternary complexes of the chosen magnetic particles. Larger animal models would not be subject to this limitation. Clearly, our findings indicate that more detailed and likely extensive formulation will be required, at least for our mouse model. Some areas of focus may include the size of the magnetic particles. TransMAG PEI is approximately 200 nm, 23 but smaller particles might be more effective in penetrating extracellular, as well as intracellular barriers in airway epithelium. The coating of the particles may also be usefully altered to increase pDNA:particle ratio and allow for more concentrated formulations to be prepared. Thus, for instance, avidinylated magnetic microspheres have been used to deliver AAV, in vitro, in the presence of a magnetic field. 37 Finally, another important variable is likely to be the shape and strength of the magnetic field. Different and perhaps stronger magnets might be able to focus the magnetic field specifically onto the target area, and thus might be more effective for magnetofection of the nasal epithelium.
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Materials and methods
Magnetic particles and magnets
Superparamagnetic iron oxide nanoparticles, coated with PEI (TransMAG PEI PEI: 800 kDa; Chemicell, Berlin, Germany), were prepared as previously described. 
In vitro transfections
The eucaryotic expression plasmid (pLux) carrying a luciferase reporter gene under the control of a cytomegalovirus (CMV) immediate early promoter was complexed with Lipofectamine 2000 (Invitrogen, Paisley, UK) or cationic lipid 67 (GL67; Genzyme Corporation, Framingham, MA, USA). Lipofectamine was used according to the manufacturer's instructions. In brief, equal volumes of pDNA and lipid were mixed at a w:w ratio of 1:2.5 (pDNA:Lipofectamine), in OptiMEM (Invitrogen, Paisley, UK) and incubated for 15 min at room temperature. Similarly, equal volumes of GL67 and pLux were mixed at a molar ratio of 1:4 (GL67:pDNA) in OptiMEM, in a total volume of 50 ml, as previously described. 31 The liposome/pDNA complexes were then coupled to TransMAG PEI at w:w ratios ranging from 1:1 to 4:1 (TransMAG PEI :pDNA). The complexing of pDNA to magnetic particles was carried out in solutions containing saline, such as OptiMEM, as previously optimized.
23
C127 cells, a murine mammary tumour cell line, were used for all in vitro experiments. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 1% penicillin-streptomycin, and 0.5% Geneticin (all Sigma, Poole, UK). A day before transfection, 10 000 cells/well were seeded into a 96-well plate. The magnetic liposome/pDNA complexes (0.04-0.2 mg pDNA/well) were added, in a total volume of 50 ml/well. Some 96-well plates were then placed onto the magnetic 96-well plate for 15 min. TransMAG PEI complexes were then removed from all wells and replaced with OptiMEM. The cells were incubated for a further 5 h, after which OptiMEM was replaced with complete media. After 48 h, cell lysates were prepared using Reporter Gene Assay Lysis Buffer (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions. The samples were freeze-thawed three times, spun at 13 000 r.p.m. for 5 min and the supernatant was stored at À801C for luciferase measurements.
Transfection of nasal epithelium in vivo
For the in vivo studies, equal volumes (50 ml) of GL67 (1.2 mM) and pDNA (4.8 mM, 1.6 mg/ml) were mixed at a molar ratio of 1:4 (GL67:pDNA) in sterilized water for injection (Arnolds Veterinary Products, Shrewsbury, UK), and incubated at 301C for 15 min. TransMAG PEI was then added to the complex, at w:w ratios of 2:1 or 4:1 (TransMAG PEI :pDNA) in the presence of 150 mM saline and incubated for 20 min at room temperature.
TransMAG PEI was also complexed to naked pDNA, using a previously optimized dose of 100 mg/mouse (data not shown). pDNA was coupled to TransMAG PEI at a 1:1 and a 2:1 w:w ratio (TransMAG PEI :pDNA), in a total volume of 100 ml, as these were the only two conditions that did not precipitate upon mixing.
Male Balb/c mice (6-10 weeks) were anaesthetized with ketase/domitor (76 and 1 mg/kg, respectively), placed onto heated boards in the supine position. A fine tip catheter approximately 0.5 mm in diameter (Portex polythene tubing, Jencons, Forest Row, UK) was inserted 2.5 mm into the left nasal cavity and the complexes were perfused at a rate of approximately 6.7 ml/min with a syringe pump (ColeÀParmer, Illinois, USA). During the procedure, the animals were placed at an angle (approximately 451) and a paper wick was placed into their mouths to prevent swallowing of solutions.
In a subset of mice, the magnetic rod, or the stack of magnets described above, was placed externally, in direct contact onto the right nostril, to attract the vector onto the septum during perfusion. The animals were exposed to the magnet during the procedure (15 min for 100 ml perfusion and 75 min for 500 ml perfusion) and for an additional 15 min afterwards. At 48 h after transfection, the mice were culled and the nasal tissue was removed and homogenized with fine scissors, in 100 ml Reporter Gene Assay Lysis Buffer (Roche, UK). The samples were freeze-thawed three times, spun, and stored as described above.
Optimization of magnetic complexes to avoid precipitation
The parameters evaluated were the pDNA dose, the total volume of the solution, the w:w ratio of TransMAG PEI : pDNA, the v:v ratio of TransMAG:pDNA before mixing, as well as the mixing order (adding TransMAG PEI to pDNA and vice versa). These studies were undertaken for both GL67/pDNA complexes and naked pDNA. In all cases, the GL67/pDNA complexes were formed before the addition of the magnetic particles, as described above. For GL67/pDNA, the pDNA doses tested were 40 and 80 mg, whereas for naked pDNA there were 100 mg. The volumes used were 100 or 500 ml and the w:w ratios were 1:1 to 4:1 (TransMAG PEI :pDNA). For the 500 ml formulations, TransMAG PEI was suspended in a 3:1 volume ratio compared to GL67/pDNA, in an attempt to facilitate rapid mixing. TransMAG PEI was added to the GTAs, in the presence of 150 mM saline, mixed vigorously and incubated for 20 min, at room temperature. The solutions were then scored for precipitation.
Quantification of reporter gene expression
Luciferase activity was measured using the Luciferase Assay System (Promega, Southampton, UK) according to the manufacturer's instructions. The total protein content of the samples was measured using the BioRad protein 
Statistical analysis
Data are expressed as means7standard error of the mean, with the open bars representing the bars exposed to the magnetic field. Independent sample t-tests or oneway analysis of variance (ANOVA) with a Bonferroni post hoc correction were carried out for all comparisons.
Where necessary, a log 10 transformation of the raw values was carried out to ensure normal distribution of the data and equal variance between groups. If that was still not achieved after the transformation, a nonparametric Mann-Whitney or a Kruskal-Wallis with a Dunns' post hoc correction were carried out instead. The null hypothesis was rejected at Po0.05.
